Pathological Complete Response to a KEYNOTE-522-Based Neoadjuvant Regimen in Synchronous Bilateral Breast Cancer with Discordant Subtypes: A Case Report
Case Reports in Oncology · 2026-11-05
DOI: 10.1159/cro/abzag094 ↗Abstract
Abstract A 50-year-old woman was diagnosed with synchronous bilateral breast cancer; triple-negative breast cancer (TNBC) in the right breast and luminal HER2-positive breast cancer in the left breast. Neoadjuvant chemotherapy using the KEYNOTE-522 regimen combined with pembrolizumab resulted in a pathological complete response (pCR) in both tumors. Next-generation sequencing (NGS) performed on pretreatment biopsy specimens identified a pathogenic BRCA1 variant in both tumors. The right tumor showed a high homologous recombination deficiency (HRD) score. These molecular findings provide a potential biological rationale for the observed sensitivity to platinum-containing chemoimmunotherapy, though further studies are required to validate this association.
EUVIMED